Compare IHS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHS | SUPN |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2021 | 2010 |
| Metric | IHS | SUPN |
|---|---|---|
| Price | $8.32 | $46.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $8.29 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.0M | 678.4K |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $17.26 | $22.70 |
| Revenue Next Year | $7.87 | $19.14 |
| P/E Ratio | $5.85 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.45 | $31.16 |
| 52 Week High | $8.95 | $59.68 |
| Indicator | IHS | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 37.60 |
| Support Level | $8.14 | $43.67 |
| Resistance Level | $8.34 | $46.89 |
| Average True Range (ATR) | 0.05 | 1.69 |
| MACD | 0.01 | -0.34 |
| Stochastic Oscillator | 51.28 | 5.43 |
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria and Sub-Saharan Africa. The majority of its revenue is derived from Nigeria.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.